Biodexa Pharmaceuticals PLC, a public limited company, has completed a series of transactions involving the issuance and exercise of warrants, as well as the filing of a prospectus supplement. On May 22, 2024, the company entered into agreements with certain accredited investors for the exercise of Series E and Series F warrants issued on December 21, 2023. These transactions resulted in the exercise of 4,036,151 warrants, leading to the issuance of an equivalent number of American Depositary Shares (ADSs), each representing 400 ordinary shares. In conjunction with these exercises, the company issued new Series G and Series H warrants, exercisable for a total of 6,054,230 ADSs at $2.50 per share. The company received approximately $6.05 million in gross proceeds before expenses and also issued placement agent warrants to Ladenburg...Show More

Biodexa Pharmaceuticals PLC, a public limited company, has completed a series of transactions involving the issuance and exercise of warrants, as well as the filing of a prospectus supplement. On May 22, 2024, the company entered into agreements with certain accredited investors for the exercise of Series E and Series F warrants issued on December 21, 2023. These transactions resulted in the exercise of 4,036,151 warrants, leading to the issuance of an equivalent number of American Depositary Shares (ADSs), each representing 400 ordinary shares. In conjunction with these exercises, the company issued new Series G and Series H warrants, exercisable for a total of 6,054,230 ADSs at $2.50 per share. The company received approximately $6.05 million in gross proceeds before expenses and also issued placement agent warrants to Ladenburg Thalmann & Co., Inc. for the purchase of 161,446 ADSs. The closing of these transactions occurred on May 24, 2024, and the details were filed with the SEC on May 28, 2024, through a Form 6-K report. The company's ADSs are listed on the NASDAQ Capital Market under the symbol 'BDRX,' with a reported closing price of $1.08 on May 28, 2024.